Your browser doesn't support javascript.
Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?
Joshi, Gaurav; Borah, Pobitra; Thakur, Shweta; Sharma, Praveen; Poduri, Ramarao.
  • Joshi G; School of Pharmacy, Graphic Era Hill University, Dehradun, India.
  • Borah P; Department of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda, India.
  • Thakur S; School of Pharmacy, Graphic Era Hill University, Dehradun, India.
  • Sharma P; Laboratory of Genomic Instability and Diseases, Department of Infectious Disease Biology, Institute of Life Sciences, Bhubaneshwar, India.
  • Mayank; Department of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda, India.
  • Poduri R; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.
Hum Vaccin Immunother ; 17(12): 4714-4740, 2021 Dec 02.
Article in English | MEDLINE | ID: covidwho-1550494
ABSTRACT
As of September 2021, 117 COVID-19 vaccines are in clinical development, and 194 are in preclinical development as per the World Health Organization (WHO) published draft landscape. Among the 117 vaccines undergoing clinical trials, the major platforms include protein subunit; RNA; inactivated virus; viral vector, among others. So far, USFDA recognized to approve the Pfizer-BioNTech (Comirnaty) COVID-19 vaccine for its full use in individuals of 16 years of age and older. Though the approved vaccines are being manufactured at a tremendous pace, the wealthiest countries have about 28% of total vaccines despite possessing only 10.8% of the total world population, suggesting an inequity of vaccine distribution. The review comprehensively summarizes the history of vaccines, mainly focusing on vaccines for SARS-CoV-2. The review also connects relevant topics, including measurement of vaccines efficacy against SARS-CoV-2 and its variants, associated challenges, and limitations, as hurdles in global vaccination are also kept forth.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Hum Vaccin Immunother Year: 2021 Document Type: Article Affiliation country: 21645515.2021.1995283

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Hum Vaccin Immunother Year: 2021 Document Type: Article Affiliation country: 21645515.2021.1995283